Bexmarilimab results published in CCR
Faron Pharmaceuticals Oy (“Faron” or the “Company”) First-in-human bexmarilimab results published in Clinical Cancer Research - Results reveal the role of Clever-1 receptor in supressing adaptive immunity - Bexmarilimab’s macrophage-targeting approach activates T-cells and drives anti-tumour immune responses in cold tumours that are not otherwise responsive to immunotherapy Company announcement, 3 June 2021 at 9.00 AM (EET) TURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announces the